|
SERINC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.08921768773962E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.83660009212394E-10 |
| Normal-vs-Stage2 |
4.00789999965845E-07 |
| Normal-vs-Stage3 |
7.64055485547033E-13 |
| Normal-vs-Stage4 |
2.64280042294729E-10 |
| Stage1-vs-Stage2 |
6.189200E-01 |
| Stage1-vs-Stage3 |
2.304400E-02 |
| Stage1-vs-Stage4 |
6.374200E-02 |
| Stage2-vs-Stage3 |
2.611000E-01 |
| Stage2-vs-Stage4 |
2.643200E-01 |
| Stage3-vs-Stage4 |
8.925400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.09801057135428E-13 |
| Normal-vs-AfricanAmerican |
5.218000E-03 |
| Normal-vs-Asian |
3.48519999970875E-07 |
| Caucasian-vs-AfricanAmerican |
5.618500E-02 |
| Caucasian-vs-Asian |
4.742400E-01 |
| AfricanAmerican-vs-Asian |
2.171400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.89195359168571E-13 |
| Normal-vs-Female |
3.39169803353911E-11 |
| Male-vs-Female |
1.265780E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.25019999908105E-08 |
| Normal-vs-Age(41-60Yrs) |
1.45849998745007E-11 |
| Normal-vs-Age(61-80Yrs) |
5.14877029900163E-12 |
| Normal-vs-Age(81-100Yrs) |
1.944070E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.518000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.008100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.896800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.620760E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.535800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.491600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.799200E-03 |
| Classical-VS-Follicular |
7.155800E-01 |
| Classical-VS-Other |
3.222400E-01 |
| Classical-VS-Normal |
3.97150090591936E-11 |
| Tall-VS-Follicular |
4.710200E-02 |
| Tall-VS-Other |
8.376000E-01 |
| Tall-VS-Normal |
1.04919961607663E-10 |
| Follicular-VS-Other |
5.048800E-01 |
| Follicular-VS-Normal |
4.80490000009937E-07 |
| Other-VS-Normal |
1.817000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.97970528859059E-11 |
| Normal-vs-N1 |
1.63549995768619E-09 |
| N0-vs-N1 |
2.366200E-01 |
|
|
